Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a prospective, single-arm, phase II clinical study. Patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have either not previously received standard therapy or have experienced treatment failure following standard therapy will be screened for eligibility and enrolled in the study after providing written informed consent.
Epistemonikos ID: 40d3745d79d0ff432cfc79838a61decdca1e9f27
First added on: Aug 26, 2026